Antagonists of calmodulin dealy injury development in the severely ischemic perfused working rat heart

• Autorzy: Beresewicz A.
• Języki publikacji: EN

Abstrakty

EN

Beręsewicz, A.: Antagonists of calmodulin dealy injury development in the severely ischemic perfused working rat'heart. Acta physiol, pol., 1988, 39 (4): 225-243. The effects of calmodulin antagonists trifluoperazine (TFP) and calimidazolium (CMZ) and of ethmozine (a phenothiazine without anticalmodulin activity) on the postischemic recovery in the perfused working rat hearts were studied. In the hearts subjected to 25 min zero-flow ischemia coronary flow, cardiac output, MVO₂ and external work recovered to about 50％of the preischemic values during 40 min of reperfusion. TFP (5 X 10⁻⁷ M and 10⁻⁶ M) or CMZ (10⁻⁷ M) improved the functional recovery to 75-94％ whereas 5 X 10⁻⁷ M ethmozine was not effective. In all experimental grpups a prolongation of the ischemic period caused a progressive deterioration of the functional recovery while the total postischemic LDH release showed an initial gradual rise followed by a later decay. TRP and CMZ prolonged the time-to-half decay of the hemodynamic functions (tHF₅₀ ) by 4-7 min and the time-to-peak of total LDH release (tLDHmax) by 5-10 min. In the hearts subjected to 0.2 ml/min low-flow ischemia tm-so and tHF₅₀ were increased to 40 min, CMZ prolonged these times by further 5-10 min. Thus, TFP and CMZ delayed the development of the. myocardial ischemic injury. Although other interpretations are possible, our data are consistent with the 'hypothesis that calmodulin-sensitive process is involved in the ischemic damage of the myocardium.

• Wydawca: -
• Czasopismo: Acta Physiologica Polonica
• Rocznik: 1988
• Tom: 39
• Numer: 4
• Opis fizyczny: p.225-243,fig.,ref.

Twórcy

autor

Beresewicz A.

• Department of Clinical Physiology, Medical Center of Postgraduate Education, Warsaw, Poland

Bibliografia

• 1. Baldepkov, G. N., Kourennaya, G. S., Ratner, E. J. (1986) The study of antiarrhythmic drug action on receptors system in myocardium. Abstracts of III Symposium oi Soviet Section oi Intern. Soc. Heart. Res. Metabolism. Structure and Function ol Cardiac Cell, Baku.
• 2. Beręsewicz, A., Karwalowska-Kryńska, E. (1986) Effect of calmodulin antagonists on hypoxia and reoxygenation damage in isolated rabbit hearts. Basic Res. Cardiol. 81. 7311-3275.
• 3. Beręsewicz, A., Wasilewska, A., Henbaczyńska-Cedro, K. (1988) Calmodulin antagonist reduces felease of malondialdehyde from isolated ischemic/reperfused rat heart. Acta Physiol. Pol. (in press).
• 4. Cheung, W. Y.: (1980) Calmodulin plays a pivotal role in cellular regulation. Science 207. 19-27.
• 5. Demkow, M., Beręsewicz, A., Mistarz, K. (1987) Protective effect of trifluoperazine on ischemic myocardium. Kard. Pol. 30. 317-327.
• 6. Farber, J. V., Chien, K. R., Mittnacht, Jr. S. (1981) The pathogenesis of irreversible cell injury in ischemia. Amer. J. Pathol. 102. 271-281.
• 7. Gutman, J., Wahlefeld, A. W. (1974) L( + )-Lactate determination, with lactate dehydrogenase and NAD. In: Bergmeyer, H. U. (Ed.) Methods in Enzymatic Analysis, pp. 1464-1467, Verlag Chemie, Weinheim.
• 8. Hearse,, D. J. (1984) Critical distinctions in the modification of myocardial cell injury. In: L. H. Opie (Ed.). Calcium Antagonists and Cardiovascular Disease, pp. 129-145, Raven Press, New York.
• 9. Hearse, D. J., Crome, R., Yellon, D. M., Wyse, R. (1983) Metabolic and flow correlates of myocardial ischemia. Cardiovasc. Res. 17. 452-458.
• 10. Higgins, A. J., Blackburn, K. J. (1984) Prevention of reperfusion damage in working rat hearts by calcium antagonists and calmodulin antagonists. J. Mol. Cell. Cardiol. 16. 427-438.
• 11. Humphrey, S. M , Thomson, R. W., Gavin, J. B. (1984) The influence of the.noreflow phenomenon on reperfusion and reoxygenation damage and enzyme release from anoxic and ischaemic isolated rat hearts. J. Mol. Cell. Cardiol. 16. 915-930.
• 12. Jennings, R, B., Reimer, K. A. (1981) Lethal myocardial ischemic injury. Amer. J. Pathol. 102. 421-455.
• 13. Johnson, J.D., Wittenauer, L. A., Nathan, R. D. (1983) Calmodulin, Ca²⁺ transporters and Ca²⁺ -transporters in nerve and muscle. J. Neurol Trans. (Suppl.) 18. 97-111.
• 14. Kannengieser, G. J., Opie, L. H., Van der Werff, T. J. (1979) Impaired cardiac work and oxygen uptake after reperfusion of regionally ischemic myocardium. J. Mol. Cell Cardiol. 11. 197-207.
• 15. Landry, Y., Amellal, M., Ruckstuhl, M. (1981) Can calmodulin inhibitors be used to probe calmodulin effects? Biochem. Pharmacol. 30. 2031-2032.
• 16. Levin, R. M., Weiss, B. (1979) Selective binding of antipsychotics and other psychoactive agents to the calcium dependent activator of cyclic nucleotide phosphodiesterase. J. Pharmacol. Exp. Ther. 208. 454-459.
• 17. Lochner, A., Van Niekerk, I., Kotze, J. C. N. (1985) Normothermic ischemic cardiac arrest of the isolated perfused rat heart: effects of trifluoperazine and lysolecithin on mechanical and metabolic recovery. Basic Res. Cardiol. 80. 363-376.
• 18. McCullough, T. E., Walsh, D. A. (1979) Phosphorylation and dephosphorylation of phosphorylase kinase in the perfused rat heart. J. Biol. Chem. 254. .7345.-7352.
• 19. Miura, D. S., Wynn, J., Torres, V., Laux, B., Keefe, D., (1986) Antiarrhythmic efficacy of ethmozine in patients with ventricular tachycardia as determined by programmed electrical stimulation. Amer. Heart J. 111. 661-606.
• 20. Miyhara; M.F Okimasu, E., M'ikasa, H., Tereda, S., Kodema, H., Utstimi, K. (1934) Improvement of the anoxia-induced mitochondrial dysfunction by membrane modulation. Arch. Biochem. Biophys. 233. 139-150.
• 21. Nayler, W. G., Elz, J. S. (1986) Reperfusion injury: laboratory artifact or clinical dilemma? Circulation 74. 215-221.
• 22. Neely, J. R., Grotychann, L. W. (1984) Role of glycolytic products in damage to ischemic myocardium. Dissociation of adenosine triphosphate levels and recovery of function of reperfused ischemic hearts. Circ. Res. 55. 816-824.
• 23. Neely, J. R., Liebermeister, H., Battersby, E. J., Morgan, H, E. (1967) Effect of pressure development on oxygen consumption by the isolated rat heart. Amer. J. Physiol. 212. 804-814.
• 24. Okumura, K., Ogawa, K., Satake, T. (1985) Effects of trifluoperazine on calcium-repleted injury in isolated ventricular strips. Basic. Res. Cardiol. 80. 556-533.
• 25. Schaffer, S. W., Burton, K. IP., Jones, H. H., Oei, H. H. (1983) Phenothiazine protection in calcium overload-induced heart failure: a possible role for calmodulin. Amer. J. Physiol. 244. H328-H-334.
• 26. Schaffer, S. W., Roy, R. S., McMcord, J. M. (1983) Possible role for calmodulin in calcium paradox-induced heart failure. Europ. Heart J. 4 (suppl. H). 81-87.
• 27. Scott, J. A., Khaw, B. A., Fallon, J. T., Locke, E., Rabito, C. A., Peto, C. A., Homey, C. J. (1936) The effect of phenothiazines upon maintenance of membrane integrity in the cultured myocardial cell. j. Mol. Cell Cardiol. 18. 1243-1254.
• 28. Steenbergen, C., Jennings, R. B. (1984) Relationship between lyso-phospholipid accumulation and plasma membrane injury during total in vitro ischemia in dog heart. J. Mol. Cell. Cardiol. 16. 605-621.
• 29. Van Belle, H. (1981) R 24571: A potent inhibitor of calmodulin-activated enzymes. Cell Calcium 2. 483-494.
• 30. Wallenstein, S., Zucker, Ch. L., Fleiss, J. L. (1930) Some statistical methods useful in circulation research. Circ. Res. 47. 1-9.
• 31. Walsh, M. P., Le Peuch, C. J., Vallet, B., Cavadore, J. C., Demaville, J. G. (1980)
• 32. Watts, J. A. (1986) Protection .of ischemic heart by Ca²⁺ antagonists. J. Moll. Cell Cardiol. 18 (suppl. 4). 71-75.
• 33. Weiss, B., Prozialek, W., Cimino, M., Barnette, M. S., Wallace, T. L. (1980) Pharmacological regulation of calmodulin. Ann. NY Acad. Sci. 356. 319-345.
• 34. Werth, D. К., Hathaway, D. R., Watanabe, A. M. (1982) Regulation of phosphorylase kinase in rat ventricular myocadium. Role of calmodulin. Circ. Res. 51. 448-456.
• 35. Wongj P. Y. K., Cheung, W. Y. (1979) Calmodulin stimulates human platelet phospholipase A2. Biochem. Biophys. Res. Commun. 90. 473-480.
• 36. Wróblewski, F., La Due, .J. S. (1955) Lactic dehydrogenase activity in blood. Proc. Soc. Exp. Biol. Med. 90. 210-213.